Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
08/2001
08/16/2001WO2001012172B1 Treatment of metastatic disease
08/16/2001WO2001010893A3 Il-16 antagonists
08/16/2001WO2001010891A3 Il-16 antagonists
08/16/2001WO2001010413A3 Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers
08/16/2001WO2001009293A3 Mammalian adhesion protease peptides
08/16/2001WO2001009185A3 Transmembrane transport proteins, nucleic acids encoding them and uses therefor
08/16/2001WO2001009173A3 Use of quinic, shikimic acids and their derivatives for preparing mannose receptor ligands
08/16/2001WO2001009115A3 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE
08/16/2001WO2001007628A3 Human synthetases
08/16/2001WO2001007595A3 Novel fibroblast growth factor and nucleic acids encoding same
08/16/2001WO2001006989A3 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
08/16/2001WO2001004354A3 Use of ras inhibitors of inhibiting muscle atrophy
08/16/2001WO2001002569A3 Human immune response molecules
08/16/2001WO2001002556A3 Agents for the diagnosis, prognosis and treatment of malignant diseases
08/16/2001WO2000058506A3 Susceptibility to psoriasis
08/16/2001WO2000057866A3 Use of azalide antibiotics for the topical treatment or prevention of ocular infections
08/16/2001WO2000049132A3 Uses of transgenic animals containing a type x collagen mutant
08/16/2001WO2000046367A3 Proteins capable of triggering g2/m transition and of interacting with cdc2- and cyclin b
08/16/2001WO2000044782B1 Ewing's tumour antigen, nucleic acid and antibodies
08/16/2001WO2000029589A8 Methioninase gene therapy for tumor treatment
08/16/2001WO1999064046A8 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-ht3 receptors
08/16/2001WO1999050658A3 Methods and compounds for modulating nuclear receptor activity
08/16/2001US20010014734 Controllers
08/16/2001US20010014676 For mammals; mixture with drug
08/16/2001US20010014674 Wound healing agent
08/16/2001US20010014668 Colonization factor antigens; epitopes; immunization against diarrheagenic Escherichia
08/16/2001US20010014666 Solution comprises purified glucagon-like peptide-1, buffering agent containing alcohol or mono/di- saccharide, and optionally ammonium sulfate; tetragonal flat rod shaped crystals formed; useful in treating diabetes and obesity
08/16/2001US20010014665 For oral administration to reduce nephrotoxicity and topically promote skin permeation in treatment of psoriasis
08/16/2001US20010014664 Viscosity; biodegradability; fibroblast growth factor
08/16/2001US20010014663 Treatment of allograft rejection with anti-angiogenic agents
08/16/2001US20010014476 Region which allows its replication comprises an origin of replication derived from a plasmid or a bacteriophage and whose functionality in the host cell requires the presence of at least one specific protein foreign to host cell
08/16/2001US20010014474 Preparing hybridoma cell line which produces antibody which specifically recognizes and binds to cell surface antigen associated with a neoplastic human cell; diagnosis, therapy
08/16/2001US20010014471 Antitumor agents
08/16/2001US20010014465 Human 4-1BB receptor splicing variant
08/16/2001US20010014464 Nucleic acid encoding follistatin-3
08/16/2001US20010014463 Lysozyme-like enzymes capable of killing cariogenic bacteria; also methods for studying the cell wall of oral bacterium, preventing spoilage of perishable items and removing dextrans from surfaces used in sugar refining
08/16/2001US20010014458 Human G-protein coupled receptor GPR6sb
08/16/2001US20010014342 Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
08/16/2001US20010014337 A peptide having substantial homology with the CBF1/RBPJk (cell binding factor-1/recombination bining protein J kappa) interaction domain of EBNA2 comprising specific peptide containing 15-20 amino acids
08/16/2001US20010014333 Hybrid heterodimeric protein hormone and method of using same
08/16/2001US20010014328 A multispecific binding molecule, comprising a first binding determinant which binds an Fc alpha receptor is not blocked by human immunoglobin A and a second binding determinant binds target cancer cell antigen
08/16/2001US20010014325 Monoclonal antibodies against leukocyte adhesion receptor beta-chain, methods of producing these antibodies and use therefore
08/16/2001US20010014323 For use in investigation, diagnosis and treatment of subjects suspected of or suffering from sulphamidase deficiency
08/16/2001US20010014319 Defective recombinant virus containing at least one inserted gene encoding all or part of lecithin-cholesterol acyltransferase (LCAT) or a variant thereof; treating or preventing dyslipoproteinaemia-related diseases
08/16/2001EP1144997A3 Methods and compounds for modulating nuclear receptor activity
08/16/2001EP1144678A3 Susceptibility to psoriasis
08/16/2001EP1144627A3 Proteins capable of triggering g2/m transition and of interacting with cdc2- and cyclin b
08/16/2001EP1123717A2 Estrogen agonist/antagonist and statin containing compositions for treating osteoporosis and lowering cholesterol
08/16/2001EP1123709A1 Preventives/remedies for liver diseases
08/16/2001EP1123692A2 Use of polyaminoacid derivatives for the treatment of Seborrhea and related cutaneous disorders
08/16/2001EP1123653A1 Use of polyamino acid derivatives as preservatives
08/16/2001EP1123509A2 Methods of diagnosing or prognosing alzheimer's disease
08/16/2001EP1123418A2 Isolated nucleic acid molecules which encode scp proteins, and uses thereof
08/16/2001EP1123414A1 Antisense modulation of integrin alpha 4 expression
08/16/2001EP1123401A1 BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP)
08/16/2001EP1123397A2 G-protein coupled receptors
08/16/2001EP1123395A2 Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
08/16/2001EP1123393A1 Follistatin-related protein zfsta2
08/16/2001EP1123392A1 Prv-1 gene and the use thereof
08/16/2001EP1123390A2 Methods and reagents for isolating biologically active peptides
08/16/2001EP1123387A2 Mn gene and protein
08/16/2001EP1123315A1 Multiple domain glycoprotein hormones and methods of using
08/16/2001EP1123314A2 USE OF A CYTOKINE-PRODUCING $i(LACTOCOCCUS) STRAIN TO TREAT COLITIS
08/16/2001EP1123313A2 Methods and compositions for the prevention and treatment of anemia
08/16/2001EP1123312A2 Human rna binding proteins
08/16/2001EP1123309A2 Cyclic tetrapeptides and their use as histone deacetylase inhibitor
08/16/2001EP1123306A1 Inhibitors of platelet activation and recruitment
08/16/2001EP1123115A1 Treatment of trauma (ie graft rejection) with liposomes containing dna encoding for ctla4ig or for anti cd40l
08/16/2001EP1123114A1 Virus-like particles for the induction of autoantibodies
08/16/2001EP1123112A1 Ionic molecular conjugates of n-acylated derivatives of poly (2-amino-2-deoxy-d-glucose) and polypeptides
08/16/2001EP1123111A1 Modulation of gene expression by combination therapy
08/16/2001EP1123110A1 Compositions and methods for promoting tissue repair using heat shock proteins
08/16/2001EP1123109A1 Contulakin-g, analogs thereof and uses therefor
08/16/2001EP1123108A1 Isolated peptides which bind to hla-b35 molecules
08/16/2001EP1123090A1 Method and composition for modulating amyloidosis
08/16/2001EP1123072A1 Anti-inflammatory and antimicrobial uses for bioactive glass compositions
08/16/2001EP0805817B1 Thiol derivatives with metallopeptidase inhibitory activity
08/16/2001EP0771189B1 Inhalation composition
08/16/2001EP0759944B1 Target cell binding chimaeric peptides
08/16/2001EP0749444B1 Hybrid human/animal factor viii
08/16/2001EP0710247B1 Process for manufacture of 1-deamino-8-d-arginine vasopressin
08/16/2001EP0702958B1 Vaginal preparation containing physiologically active peptide
08/16/2001EP0694307B1 Atopic disease remedy
08/16/2001EP0684820B1 Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
08/16/2001EP0670729B1 Use of insulin-like growth factors and analogs for TREATING RETINAL NEURONAL DISORDERS
08/16/2001EP0587639B1 Pharmaceutical compositions
08/16/2001EP0576483B1 Biocidal proteins
08/16/2001EP0552256B1 Method of treating or preventing type 1 diabetes by oral administration of insulin
08/16/2001DE10004858A1 Verwendung von Proteinkinase-Inhibitor-alpha The use of protein kinase inhibitor alpha-
08/16/2001DE10004857A1 MLP-Gen, Nukleinsäuren, Polypeptide und deren Verwendung MLP-gene nucleic acids, polypeptides and their use
08/16/2001DE10004447A1 Verfahren zur Verhinderung von Tumorwachstum A method for preventing tumor growth
08/16/2001CA2714081A1 Methods and compositions for treating conditions of the eye
08/16/2001CA2635489A1 Drug delivery apparatus
08/16/2001CA2400699A1 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders
08/16/2001CA2400497A1 Methods and compositions for generating angiostatin
08/16/2001CA2400472A1 Il-17 like molecules and uses thereof
08/16/2001CA2400299A1 Dna encoding human vanilloid receptor vr3
08/16/2001CA2400187A1 Protein c derivatives
08/16/2001CA2400186A1 Microencapsulation and sustained release of biologically active agent
08/16/2001CA2399969A1 Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof